Try our beta test site
23 studies found for:    ocrelizumab
Show Display Options
Rank Status Study
1 Recruiting A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Ocrelizumab
2 Recruiting A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Biological: Ocrelizumab
3 Not yet recruiting Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Ocrelizumab
4 Completed A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Ocrelizumab
5 Recruiting Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
Conditions: Relapsing Multiple Sclerorsis;   Multiple Sclerosis, Primary Progressive
Interventions: Drug: Ocrelizumab;   Procedure: Lumber Puncture
6 Active, not recruiting A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: Ocrelizumab;   Other: Placebo
7 Completed A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Intervention: Drug: ocrelizumab
8 Terminated A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
Condition: Rheumatoid Arthritis
Interventions: Drug: Ocrelizumab;   Drug: Placebo
9 Active, not recruiting A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Condition: Relapsing Multiple Sclerosis
Interventions: Drug: Ocrelizumab;   Drug: Ocrelizumab Placebo;   Drug: Rebif;   Drug: Rebif placebo
10 Active, not recruiting A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Condition: Relapsing Multiple Sclerosis
Interventions: Drug: Ocrelizumab;   Drug: Ocrelizumab placebo;   Drug: Rebif;   Drug: Rebif placebo
11 Available Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Ocrelizumab
12 Not yet recruiting Tolerability and Safety of Switching From Rituximab to Ocrelizumab in Patients With Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Ocrelizumab;   Drug: Rituximab
13 Terminated A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
Condition: Rheumatoid Arthritis
Interventions: Drug: methotrexate;   Drug: ocrelizumab;   Drug: placebo
14 Terminated A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)
Condition: Rheumatoid Arthritis
Interventions: Drug: methotrexate;   Drug: ocrelizumab;   Drug: placebo
15 Terminated A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)
Condition: Rheumatoid Arthritis
Interventions: Drug: methotrexate;   Drug: ocrelizumab;   Drug: placebo
16 Terminated A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: placebo;   Drug: methotrexate;   Drug: ocrelizumabu 50mg;   Drug: ocrelizumabu 200mg;   Drug: ocrelizumab 500mg
17 Active, not recruiting A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)
Condition: Rheumatoid Arthritis
Interventions: Drug: leflunomide;   Drug: methotrexate;   Drug: ocrelizumab;   Drug: placebo
18 Active, not recruiting A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: interferon beta-1a;   Drug: methylprednisolone;   Drug: ocrelizumab;   Drug: placebo
19 Active, not recruiting A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)
Conditions: Lupus Nephritis;   Systemic Lupus Erythematosus
Interventions: Drug: corticosteroids;   Drug: cyclophosphamide;   Drug: mycophenolate mofetil;   Drug: ocrelizumab;   Drug: placebo
20 Terminated A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: corticosteroids;   Drug: immunosuppressive regime;   Drug: methylprednisolone;   Drug: ocrelizumab;   Drug: placebo

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.